Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05465174 · ClinicalTrials.gov registry record · Phase 2

Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults

A Phase 2 study of Craniopharyngioma and Craniopharyngioma, Child, sponsored by Sabine Mueller, MD, PhD.

Recruiting
Registry status
Phase 2
Development phase
57
Enrollment target
19
Study locations

NCT05465174 is a Phase 2 study of Craniopharyngioma and Craniopharyngioma, Child that is actively recruiting participants, run by Sabine Mueller, MD, PhD. The registered enrollment target is 57 participants, below the 207-participant average among 6 other Craniopharyngioma trials with a reported enrollment target (72% lower). The trial reports 19 study locations across 18 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05465174, a Phase 2 study of Craniopharyngioma and Craniopharyngioma, Child, is actively recruiting participants, sponsored by Sabine Mueller, MD, PhD.

RECRUITING
Registry status
Phase 2
Development phase
57 participants
Enrollment target
19
Study locations

Study Summary

The current study assesses the tolerability and efficacy of monotherapy with pan-RAF-kinase (Tovorafenib) inhibition for the treatment of children and young adults with craniopharyngioma.

Interventions

  • DRUG Tovorafenib

Study Locations (19)

California

  • Rady Children's Hospital/University of California, San Diego - San Diego
  • University of California, San Francisco - San Francisco

Alabama

  • University of Alabama at Birmingham - Birmingham

Florida

  • University of Florida - Gainesville

Illinois

  • Ann & Robert H. Lurie Children's Hospital of Chicago - Chicago

Indiana

  • Riley Hospital for Children at Indiana University Health - Indianapolis

Maryland

  • John Hopkins University - Baltimore

Massachusetts

  • Dana-Farber/Boston Children's Harvard Medical School - Boston

Michigan

  • University of Michigan - Ann Arbor

Trial Details

FieldValue
Enrollment Target 57 participants
Start Date 2022-09-12
Est. Completion 2028-03-01
Phase Phase 2

Sponsor

Sabine Mueller, MD, PhD

12 total trials

What the Registry Record Tells You About NCT05465174

The ClinicalTrials.gov registry entry for NCT05465174 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 207-participant average among 6 other Craniopharyngioma trials with a reported enrollment target (72% lower). The listed sponsor is Sabine Mueller, MD, PhD, which has 12 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Craniopharyngioma appearing as the primary indexed condition, and to 1 intervention - of which Tovorafenib is the first listed.

NCT05465174 reports 19 study locations spanning 18 distinct geographic areas - top geographies include California, Alabama, Florida.

Frequently Asked Questions

What is clinical trial NCT05465174 about?

NCT05465174 is a clinical study titled "Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults". The current study assesses the tolerability and efficacy of monotherapy with pan-RAF-kinase (Tovorafenib) inhibition for the treatment of children and young adults with craniopharyngioma.

What is the current status of trial NCT05465174?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 57 participants. The study started on 2022-09-12. Estimated completion is 2028-03-01.

What conditions does trial NCT05465174 study?

This clinical trial studies the following conditions: Craniopharyngioma, Craniopharyngioma, Child, Recurrent Craniopharyngioma.

What interventions are being tested in trial NCT05465174?

The interventions under investigation include: Tovorafenib (DRUG).

Who is sponsoring clinical trial NCT05465174?

This trial is sponsored by Sabine Mueller, MD, PhD, which has 12 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05465174 being conducted?

This trial has 19 study locations across Alabama, California, Florida, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Craniopharyngioma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.